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8-Isoprostane Levels in Exhaled Breath Condensate of Pregnant Women Compared to
Non-Pregnant Women; Is There a Baseline Difference?
Rosemary Szollas
ABSTRACT
This study investigated whether or not there was an overall difference in the
pulmonary oxidative marker, 8-isoprostane (PGF2-α), found in exhaled breath
condensate, during pregnancy versus the non-pregnant state. The utility of this
information was important secondary to the effect of maternal asthma on pregnancy and
outcome, as it has been demonstrated in past studies that overall pregnant females with
asthma have been shown to have an increased risk of exacerbation requiring medical
intervention.
The primary goal of this study sought to determine if there is a difference in
PGF2α levels in the exhaled breath condensate of pregnant versus non-pregnant females.
In order to achieve this goal a cross-sectional study was performed consisting of two
groups and were compared to one another.
A group of 16 healthy, non-pregnant females aged 18-35 years old was compared
to a group of 6 healthy, pregnant females in their third trimester of pregnancy. Both
groups exhaled breath condensate was collected and 8-isoprostane levels determined and
compared to each other. Both groups compared did not report a history of environmental
allergies, asthma, and smoking. The non-pregnant group showed a mean 8-isoprostane
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level of 11.513pg/ml (C.I. 8.7633- 14.263). The pregnant group showed a mean 8isoprostane level of 17.34 pg/ml (C.I. -4.209-38.889).
Although a crude observable difference between the means of the two groups was
determined, this pilot study did not show a statistically significant difference between the
means of the pregnant versus non-pregnant group when they were statistically compared.
This finding is primarily due to the small sample size of both groups. A power
calculation determined that each group would require 25 participants in order to establish
a statistically significant difference in the 8-isoprostane levels in exhaled breath
condensate.
The implication is that a larger scale study is needed in order to conclusively
determine if there is a statistically significant difference between the exhaled breath
condensate 8-isoprostane levels in pregnant versus non-pregnant females.

vi

Introduction
Isoprostanes
Isoprostanes are derived from membrane lipids via peroxidation with compounds
such as free radicals and reactive oxygen species1. This non-enzymatic production of
isoprostanes catalyzed by free radicals was first described by Morrow and colleagues in
1990. It is distinctly different from the classical enyzmatically produced isoprostanes via
cyclooxygenase (COX) enzymatic pathways (Figure 1). Since their discovery, the
usefulness of these compounds as bio-markers in various disease states has been studied.
In particular, 8-isoprostane or PGF2α, as a marker of oxidative stress in patients with
asthma has been studied by Montushi and colleagues in 1999.2 Measurement of PGF2α
has been done by collection of exhaled breath condensates (EBC). This method of
collection and analyzing oxidative products in the lung allows for a simple non-invasive
mean of examining the human lower respiratory tracts3.
Elevated levels of 8-isoprostanes have shown to correlate with level of disease
severity in various disease states. Just why this occurs is not fully understood. 8isoprostane produces a number of biological responses, such as smooth muscle
contraction, vasoconstriction, and platelet activation1. These responses are thought to be
a result of an isoprostane receptor binding and subsequent signaling pathway involving
phospholipase and kinase enzymatic activity resulting in Ca ion channel
activation1.Various other markers have been found in the breath and typically vary by
1

disease state. In particular, PGF2α in the exhaled breath condensate, plasma, and serum
has been found to be elevated in individuals with asthma. Two separate studies have
shown PGF2α to be elevated in a group of asthmatic children compared to a group of
non-pregnant children.4, 5
Figure 1. Mechanisms leading to lipid peroxidation in asthma.6
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Other studies have shown 8-isoprostane levels to be elevated in severe respiratory failure
in infants.7 Therefore various disease states exist where exhaled breath condensates have
been showed to be elevated.
Pregnancy
Not surprisingly, given its biological responses, 8-isoprostane has also been
studied in its relationship to a healthy state and various disease states during pregnancy.
8-isoprostane, as previously discussed, produces smooth muscle contraction,
vasoconstriction, and platelet activation1. Preeclampsia is defined as a pregnancydependent syndrome diagnosed on the basis of increased blood pressure and proteinuria.
Endothelial dysfunction is hallmark of preeclampsia and is central in explaining the main
features of preeclampsia: hypertension, edema, proteinuria, and activated homeostasis8.
For example, plasma concentrations of free 8-isoprostane has been found to be
significantly greater in a study analyzing levels before delivery in patients with
preeclampsia than in control subjects.8 It is thought that oxidative lipid derivatives are
uteroplacental compounds that may cause dysfunctional maternal endothelium.8
Recently, a study reported an increased content of lipid peroxides in preeclamptic
decidual placental tissue in preeclamptic patients at delivery compared with controls8. In
addition, another study by Moretti and colleagues demonstrated increased markers of
oxidative stress in preeclamptic women versus uncomplicated pregnancy and nonpregnant controls by measuring various volatile organic compounds in the exhaled breath
condensate of these women9.
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Although levels of 8-isoprostanes have been shown to be elevated in the exhaled
breath condensate of individuals with asthma, no study to date has measured the levels of
8-isoprostane in the exhaled breath condensate of pregnant females. Asthmatic females
who become pregnant have been demonstrated to be more at risk of low birth weight
neonates, pre-term delivery, and complications such as preeclampsia, especially in the
absence of actively managed asthma treated with inhaled corticosteroids.10 These
mechanisms responsible for changes in asthma with pregnancy, or alterations in
pregnancy outcomes due to asthma have not been thoroughly explored.
Asthma is a chronic inflammatory disorder of the airways involving variable
airflow obstruction and increased airway responsiveness to a variety of stimuli. The
airway mucosal inflammatory response in asthma is characterized by increased vascular
permeability with edema of airway walls, mucus hypersecretion with small airway
plugging and infiltration with inflammatory cells, typically eosinophils.6 The role of
oxidant and antioxidant in asthmatic airway inflammation is ill-defined. Isoprostanes are
one of the groups of lipid peroxidation products that contribute to the pathophysiological
changes seen in asthma.6 8-isoprostane, in particularly, has been demonstrated to be
elevated in certain individuals with various disease states, including asthma. These
responses may be partially the result of elevated levels of 8-isoprostane.2 As previously
stated, 8-isoprostane is a known smooth muscle constrictor, as well as vascular
constrictor, it has also been demonstrated to cause airway hyperresponsiveness and
airway obstruction, as well as plasma exudation.11 effects of 8-isoprostane in asthma can
are listed in Table 1 below.
4

Table 1. Effects of isoprostanes (8-iso-prostaglandin (PG)F2 ) in asthma6
In vitro/animal models:

Human studies:

Smooth muscle constriction
22, 23
Airway hyperreponsiveness
24
Airway obstruction 25

8-iso-PGF2 in asthma (plasma 28; breath condensate
29)

Plasma exudation 25
Vascular constriction 26, 27

8-iso-PGF2 with asthma severity (plasma 28; breath
condensate 29)
8-iso-PGF2 with allergen challenge (urine and
bronchoalveolar lavage 30)

Given that mechanisms responsible for changes in asthma with pregnancy, or
alterations in pregnancy outcomes due to asthma have not been thoroughly explored, it
seems prudent that more research in this are be done as to why this occurs. It is well
known that pregnancy alone produces pulmonary changes including increased tidal
volume leading to increased minute ventilation leading to an increased PAO2 and
decreased PACO2 and PaCO2. However, whether or not an increase in oxidative stress
in the lungs of the pregnant female occurs, also remains unknown. The effect of
pregnancy on asthma consensus has remained the same for many years that one-third
worsens, one-third remain the same and one-third improve. Regardless, those that
worsen are at an increased risk of delivering low birth weight neonates, pre-term delivery
and complications including preeclampsia. In addition to the increased risk of poor
outcomes, pregnant females with asthma have an increased risk of an exacerbation
requiring medical attention which may also increase the risk of a poor outcome.10
5

Since reducing asthmatic inflammation and preventing exacerbations contributes
to improved outcomes in outcomes for mother and fetus it becomes apparent that studies
in this area should be focused on understanding changes in airway inflammation in
pregnant females with asthma, which may lead to more effective treatment and target
management of pregnant asthmatic females.10
Exhaled Breath Condensate
Exhaled breath condensate collection (EBC) is a noninvasive tool to collect breath
in order to analyze its contents. The method involves an individual breathing into a
cooled chamber for approximately 15 minutes. The condensed breath is then analyzed
for various substances.12
Figure 2. Schematic representation of a EBC collection apparatus13

As previously discussed 8-isoprostane measurements in the exhaled breath
condensate of pregnant females have not been performed to date. This method of
6

collection and analyzing oxidative products in the lung allows for a simple non-invasive
mean of examining the human lower respiratory tracts3.
The appeal of EBC lies in its ability to non-invasively collect a wide range of
nonvolatile molecules from the respiratory tract.12 However despite its utility with
respect to the noninvasive nature EBC portrays, there are drawbacks to analyzing breath
in this manner. One of the major problems lies in that of dilution which probably affects
the concentration of most biomarkers analyzed with in EBC. In addition, ambient air
pollutants may influence biomarkers. Naturally EBC contains mostly water vapor,
approximately >99.99%.12 Previous studies done in attempts to produce repeatability in
measuring substances were unsuccessful and showed to be variable between subjects and
within repeated samples of the same subject.12
The collection chamber of the device and container that collects, cools, and stores
the breath is composed either of glass, polystyrene or polypropylene. The composition
the EBC may be altered by the adhesive properties of the material from which the
container is made. This can be minimized by using a polypropylene container, as less
adsorption occurs as compared to polystyrene.13
In addition, collection technique to minimize saliva contamination is one of the
most important concerns regarding the collection procedure. Certain substances such as
nitrite and hydrogen peroxide present in high quantities can contaminate sample data
interpretation. This can be minimized by keeping the mouth dry during collection.13
Table 2 given below illustrates the various advantages and limitations of
collection and analysis of exhaled breath condensate collection.
7

Table 2. Advantages and limitations of collections and analysis of exhaled breath
condensate13
Advantages
1. Simple, point-of-care intervention
2. Inclusive rather than intrusive (e.g., healthy children, mechanically ventilated
neonates)
3. Domiciliary
4. Longitudinal sampling
5. Nonvolatile compounds associated with pulmonary pathophysiology
6. Amplified DNA and RNA from prokaryotic and eukaryotic cells
7. Pharmacokinetics/pharmacodynamics of drugs
8. Solute clearance
Limitations
1. Lack of standard breath-sampling method
2. Not anatomic site specific
3. Lack of evidence for the origin of the aerosol particles (bronchi versus terminal
airways)
4. Concentration artifact (due to evaporation of samples)
5. Feasibility and utility of biomarkers unrelated to oxidative stress not tested
6. Little information on biomarkers of interstitial lung disease
Research Question
Is there a baseline difference between 8-isoprostane levels in the exhaled breath
condensate of pregnant women versus those levels in non-pregnant females?
Hypothesis
The null hypothesis states that there was no difference in the exhaled breath
condensate oxidative marker PGF2α in pregnant females in their third trimester of
pregnancy versus non-pregnant females. The alternative hypothesis states that there was
a difference between the exhaled breath condensate oxidative marker PGF2α in pregnant
females in their third trimester of pregnancy versus non-pregnant females. The utility of
the study may prove to provide a better understanding of oxidative stress in the pregnant
8

state and may prove to provide a baseline measurement of PGF2α levels in the
monitoring of airway, and other disease states in pregnancy.
Goals and Objectives
The primary objective of this study serves to determine if there is a difference in
PGF2α levels in the exhaled breath condensate of pregnant versus non-pregnant females.
In addition, the following goals will be were 1) To assess the applicability of measuring
baseline PGF2α levels in pregnant females versus non-pregnant females as a measure of
oxidative stress 2) To begin to provide an examination of the generalizability of
measurements of exhaled breath markers to pregnant populations, which may serve as the
basis for a larger and more in-depth study 3) To examine whether baseline 8-isoprostane
levels are appropriately representative of healthy pregnant females.
Utility and Significance
This study was unique in that it examined exhaled breath condensate levels in the
breath of pregnant females which has not been previously performed. The utility of the
study proved to provide a better understanding of oxidative stress in the pregnant state
and proved to provide a baseline measurement of PGF2α levels in the monitoring of
airway and other disease states in pregnancy.
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Materials and Methods
Study Design
The study design was a cross-sectional design comparing two groups: a group of
pregnant women ages 18 to 35 years in their third trimester and a group of non-pregnant
women in the same age group. Exposure consisted of pregnancy and non-exposure
consisted of non-pregnant. The outcome consisted of levels of PGF2α oxidative marker
in exhaled breath condensate. Both groups were screened to exclude those with a recent
history of upper respiratory infections or smoking and any history of environmental
allergies or lung disease. In addition any individual in the pregnant group was excluded
for any complication of pregnancy, including but not limited to gestational diabetes,
hyperemesis gravidarum, preeclampsia, hypertension, or any other complication of
pregnancy.
Inclusion criteria include female sex, within the age range of 18-35 years, nonpregnant state (including individuals that have previously been pregnant), and pregnant
state – specifically within the third trimester of pregnancy. Informed consent was
obtained before any testing began.
Facilities and Equipment
The participants were seen at the College of Public Health at the University of
South Florida in the Breath Laboratory (MHH Room 323). The records were maintained
in a secured cabinet in this room. The key to access the laboratory was distributed by the
University of South Florida only to authorized personnel (obtained through the College of
Public Health).
10

Exhaled breath condensate samples were collected using Jaeger air condensing
device (Jaeger, Wuerzburg, Germany 1999). The Jaeger instrument was located in the
Breath Lab – MHH room 323. Samples were stored at approximately -70 degrees
Celsius in The Breath Lab freezer. Once samples were ready to be analyzed they were
removed from the freezer and de-thawed and analyzed using a commercially available
enzyme linked immunoassay (EIA) kit, ordered from Caymen Chemical.

The EIA kits

were processed on a 96 well plate and analyzed using a spectrophotometer (μQuant
Universal Microplate spectrophotometer,2004), which is also available within the Breath
Lab (MHH Room 323). All samples were used in their entirety.
Spirometry was performed using the KoKo spirometry software and devices also
located within the Breath Lab – Room MHH 323. Mouthpieces needed for performing
the testing were disposable and located with in the Breath Lab.
Participant Recruitment
Subjects were recruited to volunteer to participate in the study through a one time
visit to The Breath Lab (Room MHH 323) over a range of months spanning from
November 2005 to March 2006. Volunteers were recruited through primarily three
mechanisms: 1) Advertisements in the form of a poster for non-pregnant and pregnant
females were displayed in various areas throughout the University of South Florida
Tampa campus and the Tampa General Hospital Genesis OBGYN clinic (Appendix A,B)
2) A mass email targeting female students and staff in the University of South Florida
health science centers was sent out twice 3) Researchers personally manned a booth
located in the Tampa General Hospital Genesis OBGYN clinic to recruit in person.
11

Researchers did not approach volunteers; rather potential subjects voluntarily approached
the booth.
Study Subjects and Restrictions
Healthy pregnant and non-pregnant female subjects were recruited who denied
any history of environmental allergies, asthma, or other lung diseases. Also, they must
not have suffered from any recent upper or lower respiratory tract infections. Subjects
must also have no significant smoking history as defined by less than one-half pack-year
history of smoking, no smoking within the past 2 years, and no significant second-hand
smoke exposure. Subjects must refrain from strenuous exercise, food, or drink for one
hour prior to the test.
Pregnant subjects were restricted to the third trimester of pregnancy. Previous
history of pregnancy or delivery did not exclude subjects. Gestational dates were taken
in the medical history portion of the questionnaire form (Appendix A).
Study Questionnaire and Eligibility
In order to determine eligibility for potential healthy subjects, subjects were initially
asked a series of questions. The questions were asked by telephone when the subject
called in response to a recruitment flyer or email. If the potential subject denied any
previous history of environmental allergy, denied any recent URI infections within the
past two weeks, denied any chronic diseases and met the age criteria range the participant
was scheduled for an appointment for testing with in The Breath Lab.
Once the subject was met in the Breath Lab the Health Questionnaire was given
to each subject. Responses were reviewed by researcher and subject in a private cubicle.
12

Any medications and health problems were reviewed by the researcher. If subjects met
inclusion criteria they were invited to then move on to the informed consent
documentation in order to participate in the study.
Physical Examination
All subjects were visually inspected for any cyanosis and clubbing. Also,
auscultation of the heart and lungs was performed prior to any breathing tests and at the
conclusion of each visit. In auscultation, a stethoscope is used to listen to both heart
sounds and breath sounds. Auscultation is routinely and correctly done while disrobed,
however, for our purposes assessment was done over outer garments. Pregnant females
were examined identically to their non-pregnant counterparts; of note, gestational age
was not assessed on physical examination of pregnant females.
Exhaled Breath Condensate Collection and Storage
Data Collection and 8-isoprostane Analysis
Exhaled breath condensate samples were collected using Jaeger air condensing
device (Jaeger, Wuerzburg, Germany 1999). The Jaeger instrument was located in the
Breath Lab – MHH room 323. The Jaeger instrumentation was turned on at least 15
minutes prior to EBC collection in order for adequate cooling time of the collection
chamber to approximately -30 degrees Celsius. All valves and collection tubing was
cleaned with cavicide solution and thoroughly dried prior to use. A disposable mouth
piece and nose clip was given to each subject for collection. Apparatus was assembled
and subjects were asked to sit in a chair during the fifteen minute collection time.
Individual were asked to breathe tidally through their mouths, after a nose clip was
13

applied, into the two-way non-re-breathable mouth piece connected to the collection
chamber portion for a total of fifteen minutes. Subjects were asked to discard any
excessive saliva produced into a tissue periodically. Reading material was provided to
each subject and timer was sent to 15 minutes with alarms at 10 and 5 minutes remaining.
Subjects were notified that removal of their mouth from the tubing in order to cough,
sneeze, etc was permitted. However, subjects were instructed that refraining from
removing their mouth from the tubing was ideal in order to optimize sample collection.
After fifteen minutes, collection chamber cups were unscrewed from the chamber and
breath condensate was immediately transferred to cryo safe storage tubes in a split
sample using an analytic pipette. On average two ml of condensate was obtained and 1
ml stored in each tube. Samples were then capped and placed in a -70 degree Celsius
controlled freezer. Tubes were pre-labeled with subject identification numbers that
identified samples with individual subjects. Key sample ID sheets were stored in a
laboratory workbook in Room MHH 323. Samples were collected in this manner from
November 2005 to March 2006.
8-isoprostane concentrations were measured in pregnant and non-pregnant subject
samples using a commercially available enzyme immunoassay (EIA) kit (Cayman
Chemical Company, 8-isoprostane EIA kit model # 516351, Ann Arbor, MI). The 8isoprostane detection limit for the kit is 5 pg/ml. Normal Plasma 8-isoprostane levels for
healthy subjects: 40-100 pg/ml (Cayman Chemical), Normal Urine 8-isoprostane levels
for health subjects: 10-50 pg/ml (Cayman Chemical), exhaled breath condensate
measurements were not provided by Cayman Chemical. Exhaled Breath Condensate 814

isoprostane levels (two different studies) demonstrated 8-isoprostane levels in a sample
of 10 children (male) asthmatics - levels were 9.4-29.5 pg/ml, same study sampled 10
healthy children (male) – levels were 2.1-3.0 , (Baraldi, et.al., Thorax2003).
8-isoprostane levels were demonstrated in a sample of 12 healthy children – avg. of
34.2+/-4.5 pg/ml, compared to a group of 12 asthmatic steroid naïve children – avg of
56.4+/-7.7. (Baraldi, et.al., Chest 2003).
Analyzing the 8-isoprostane kit was done via spectrophotometry (μQuant
Universal Micro plate spectrophotometer,2004). Absorbance readings of the EIA kit
plates were taken according to the manufacturer’s recommendation at 420 nm, 977 nm
and 900 nm (the higher wavelengths were taken to negate background measurements).
The EIA 8-isoprostane EIA kit detects 8-isoprostane starting from a concentration of 5
pg/ml. The intra and interassay precision for the kit is depicted below (Figure 3).
Precision which is the component of accuracy that is concerned with the consistency of
the stability of results is demonstrated in Figure 3 as the degree to which the kit provides
consistent results from one application to the next.
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Figure 3. Cayman chemical 8-isoprostane kit precision curve (Cayman Chemical, kit
number 516351)

The EIA 8-isoprostane laboratory analysis kit works via an Enzyme Linked
Immunoassay Analysis (ELISA) method. It is based on the competition between 8isoprostane and 8-isoprostane-acetylcholinesterase (AChE) for a limited number of 8isoprostane-specific rabbit antiserum binding sites. So, the concentration of AChE is
known, and the concentration of 8-isoprostane is unknown. The reaction between bound
AChE and the antiserum binding sites produces a yellow color which is absorbed at 412
nm of light via the spectrophotometer. Therefore the amount of 8-isoprostane in each
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sample is inversely proportional to the amount of bound 8-isoprostane AChE, which is in
turn directly proportional to absorbance. (See below).
Absorbance α {Bound 8-Isoprostane Tracer} α 1/{8-Isoprostane}
In order to calculate concentrations from the absorbance values the following manner:
1. We average the absorbance readings from the NSB wells. (NSB well = nonspecific binding that occurs even in the absence of antiserum – this artificially
elevates total antiserum bound).
2. We average the absorbance reading from the B0 wells (B0 is the max tracer the
antiserum can bind in the absence of free analyte).
3. We subtract NSB average from the B0 avg. This is the corrected B0 or the actual
real maximum amount bound.
4. We calculate % B/B0 (%sample or standard bound /maximum bound) for all our
sample wells. Once this is done we can use the standard curve to locate the
%B/B0 and find the corresponding concentration on the x- axis.
The standard curve was produced via a set of known concentrations of 8isoprostane provided in the EIA kit.
Acquisition of Spirometry
Spirometry, which is a common clinical method employed in assessing lung
function, was performed on each subject after collecting exhaled breath condensate. The
Koko spirometer was used and calibrated using a standard 3-liter syringe to ambient
temperature, humidity, and barometric pressure at least once a day on days when
participants were examined. The spirometer was additionally re-calibrated when at least
17

six hours had elapsed since the prior calibration or at the discretion of the examiner. The
raw FEV1 and FVC measurements obtained for each participant were automatically
compared to their predicted normal values based on age, ethnicity, weight, height, and
non-smoking status in determining their percent of predicted values using parameters as
set forth by Crapo et. al.
The spirometry parameters examined on each study participant included FEV1,
FVC, FEV1/FVC ratio, and the flow-volume loop. At least three spirometric
measurements were obtained on each subject, with at least one flow-volume loop
showing good effort. Proper technique was ensured by evaluating the flow-volume curve
and continuance of the expiratory maneuver for at least six seconds according to ATS
criteria.
A nose clip was placed on the subjects’ noses during the study to prevent nasal
breathing in order to obtain more accurate spirometry results. Subjects were asked to
forcibly exhale for at least six seconds through a disposable single-use filter after
maximal inspiration, followed by another maximal inhalation. The maneuver was
demonstrated to them to help achieve consistency.
Any subject with abnormal spirometry measurements was notified of this
information and advised to consult a healthcare provider and disqualified from the study.
All subjects with an FEV1/FVC ratio greater than 70% of predicted, FEV1 greater than
80% of predicted, FVC greater than 70% of predicted, and a normal appearing flowvolume loop were eligible for the study by spirometric criteria.

18

Adverse effects were unlikely to occur during this phase of the study because
subjects identified themselves as being in good health, the room was temperature
controlled, and this phase of the study was brief in duration. All subjects were seated
during the spirometry. In the event that adequate trials could not be obtained in the
seated position as demonstrated by their flow-volume loops, subjects were asked to stand
and instructed on safety precautions in the event of symptoms.
Nonetheless, there was the slight possibility of unusual symptoms such as
lightheadedness, dizziness, chest pains, palpitations, or shortness of breath during the
spirometry from overexertion in breathing. As a precaution, subjects were instructed to
stop, be seated, and notify the physician examiner immediately if they experienced any
symptoms at any time.

19

Results
Study Population Characteristics
The study population consisted of 22 subjects total; a total of 17 non-pregnant
females and 5 pregnant females. Pregnancy dates in terms of weeks ranged from 25-32
weeks. The age of the population ranged from eighteen to thirty five years with a median
age of twenty-three years. Fourteen of the twenty-two subjects’ occupations were
students, one a teacher, two waitresses, one coordinator, one scientist, and one lab tech.
None of the subjects were smokers, and one reported a past smoking history of 2 packyear history. Sixteen of the twenty-two subjects reported no past medical history
problems. Nine of the twenty-two subjects reported no use of over the counter
medications, vitamins or supplements.
Date of onset of last menstrual cycle was asked and recorded for non-pregnant
subjects and ranged from 1-28 days with a mean of 14. Symptoms of cough, phlegm
production, itchy or runny nose, throat irritation, and chest tightness or pain was asked on
a four point scale zero = none, one = a little, two = moderate, three = very much. One
subject reported throat irritation and rated it as a little. Two subjects reported cough and
both rated it as a little. Five subjects reported phlegm production one reported it as
moderate, four reported it as a little. Four subjects reported an itchy or runny nose and
three reported it as a little, one reported it as moderate. One subject reported chest
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tightness or pain and rated it as a little. Table 3 lists population characteristics, as well as
Appendix I.
Table 3. Demographic characteristics of subjects both pregnant and non
pregnant
Subjec
t
A1
A2

Occupatio
n
Student
Student

Preg Weeks
nant
No
No

Menses
14
7

Smokin
g
0
0

A3

Student

No

21

0

A4
A5
A6
A7
A8

Student
Student
Teacher
Student

No
No
No
No
No

21
14
21
28
5

0
0
0
0
0

A9
A10

Student
Sales

No
No

10
7

0
0

A11
A12
A13

Student
Student
Student

No
No
No

21
14
21

0
0
0

A14
A15

7
14

0
0

A16

Waitress
No
Coordinato No
r
Student
No

1

0

A17
B18
B19

Student
Lab Tech
Scientist

No
Yes
Yes

30
31

14
0
0

0
0
2

B20

Waitress

Yes

32

0

0

B21

Student

Yes

25

0

0

B22

Student

Yes

25

0

0
21

PMH

Meds

Age

Hernia
30
Insomni OCP/Ben 22
a
/Flex
OCP/MV 23
I
25
20
OCP
23
21
Food
20
allergy
24
Childhd OCP/Mot 20
asthma rin
29
28
OCP/Mot 20
rin
Celebrex 18
Motrin
28
Migrain Axert
e h/a
OCP

Gestati
on.
DM

25
24
35
33

Effexor/
MVI
Glyb/MV 26
I
MVI/
Tylen
MVI

20
28

*OCP = oral contraceptive pill, Ben = Benadryl, Flex = Flexeril, MVI = multivitamin
8-Isoprostane Measurements
The data obtained from analyzing exhaled breath condensate samples from study
subjects using the 8-isoprostane EIA kit (Cayman Chemical) are given below in graph
and tabular forms. The standard curve used to calculate 8-isoprostane concentrations is
given in Appendix K and L. Appendix K standard curve shows values prior to removing
concentrations 500 pg/ml and 250 pg/. Removal of these concentrations as shown in
standard curve showed no significant change in concentration calculations for study
samples. 8-isoprostane concentrations obtained from standard curve were used for
biostatistical manipulations.
Table 4. 8-isoprostane concentrations in pregnant and non-pregnant females.
Sample ID
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A15
A16
B1
B2
B3
B4
B5

#1 – CONC
(PG/ML)
4.182
16.925
8.803
18.469
5.372
7.311
8.048
24.335
24.421
8.048
9.837
16.901
11.533
11.389
38.277
12.971
13.502
10.805
52.832
8.349

#2- CONC
(PG/ML)
7.298
14.207
4.374
8.700
10.199
8.553
10.690
16.402
11.708
11.368
6.188
18.010
5.770
8.120
14.207
10.655
21.182
4.642
42.412
-

#3 – CONC
(PG/ML)
16.689
16.498
7.555
13.759
7.538
5.979
11.368
15.625
13.945
10.621
12.744
11.116
9.616
7.967
13.684
5.562
10.881
6.313
48.122
4.954

AVG

SD

9.389
15.877
6.911
13.642
7.703
7.281
10.035
18.788
16.692
10.012
9.590
15.342
8.973
9.159
22.056
9.730
15.188
7.253
47.789
6.651

6.511
1.462
2.284
4.886
2.417
1.288
1.754
4.820
6.787
1.742
3.285
3.702
2.935
1.933
14.050
3.790
5.354
3.187
5.218
2.401

A = NON-PREGNANT, Mean = 11.51333, B = PREGNANT, Mean = 16.64

22

Concentrations were calculated as a function of the light absorbance of the 8isoprostane AChE tracer which is indirectly proportional to the concentration of 8isoprostane.
Given below in figures 4 and 5 are pregnant and non-pregnant concentrations
obtain from subject exhaled breath condensate samples.
Figure 4. 8-isoprostane concentrations taken from samples in pregnant females
8 - Is o p r o s t a n e L e v e ls in P r e g n a n t F e m a le s
60
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8 - is o p r o s t a n e
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0
1

2
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5
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Figure 5. 8-isoprostane concentrations in samples taken from non-pregnant females
8 - Is o p r o s t a n e le v e ls in n o n - p r e g n a n t
f e m a le s ( p g / m l)
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Table 5 depicts standard curve values used for concentration calculations. These
values were obtained by using known 8-isoprostane concentration standards given in the
kit.
Table 5. Standard concentrations (known) and actual absorbance concentrations detected
STD #
1
2
3
4
5
6
7
8

Known
Conc
(pg/ml)
500.000
250.000
125.000
62.5000
31.300
15.600
7.800
3.900

Calc conc
#1
(pg/ml)
207.790
94.526
70.312
26.648
17.383
9.304
4.516

Calc
Conc #2
(pg/ml)
164.255
86.222
82.303
28.106
11.143
6.860
5.228
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Calc
conc#3
(pg/ml)
166.470
141.009
90.090
34.964
20.294
4.870
-

AVg

SD

179.505
107.253
80.902
29.906
16.273
7.011
4.872

24.521
29.528
9.963
4.441
4.675
2.221
.504

Table 6. Standard concentrations (known) and actual absorbance concentrations detected
using standard curve without known concentrations 500pg/ml, 250 pg/ml and 125 pg/ml
STD #

Known
Conc
(pg/ml)
500.000
250.000
125.000
62.5000
31.300
15.600
7.800
3.900

1
2
3
4
5
6
7
8

Calc conc
#1
(pg/ml)
-

27.485
18.450
9.700
4.296

Calc
Conc #2
(pg/ml)
-

Calc
conc#3
(pg/ml)
-

AVg

SD

-

-

28.807
11.753
6.940
5.096

57.886
34.683
21.408
4.693
-

57.886
30.325
17.204
7.111
4.969

3.832
4.947
2.508
.565

Utilizing the standard curve data shown in table 6 above to obtain sample data
concentrations for subjects did not statistically alter calculated sample concentrations.
The statistical calculations for 8-isoprostane concentrations of non-pregnant and pregnant
subjects are given below in Table 8.
Table 7. Spirometric data for all subjects tested including pregnant and non-pregnant
females
Subject Number
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A15
A16
A17
B1
B2
B3
B4
B5

FEV1/FVC
93%
111%
90%
98%
77%
84%
91%
88%
94%
97%
87%
96%
99%
91%
88%
94%
92%
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No subjects were excluded based on spirometric measurements. The above
values do not classify any of the subjects as having an obstructive respiratory component.
Biostatistical Data for 8-Isoprostane Measurements
Table 8. Statistical analysis of mean 8-isoprostane values of 20 subjects tested
Statistical Measure

Non-Pregnant

Pregnant

N

15

5

Mean

11.513

17.34

Median

9.6

9.7

Mode

10.0

Standard Deviation

4.966

17.355

Skewness

0.841

2.039

Coeff Variation

43.131

100.08

Sum Weights

15

5

Sum Observations

172.7

86.7

Variance

24.659

301.193

Kurtosis

-.2966

4.225

Std Error Mean

1.282

7.761

Lower CL of the mean

8.7633

-4.209

Upper CL of the mean

14.263

38.889

Lower CL of Std Dev

3.6356

10.398

Upper CL of Std Dev

7.8317

49.87

26

The data given above show a difference between the means of the two groups.
The standard deviation of each group is large and demonstrates a largely skewed set of
data in each of the two sets. In addition the Lower CL of the means and upper CL for the
means of each group overlap.
Performing a T-test on the data in order to determine if the difference between the
means of the two groups was significant the following data was obtained as shown in
Table 9 below.
Table 9. T-tests used to analyze difference between means of the two groups
Variable

Method

Variances

DF

T value

Pr > │t│

8-iso

Pooled

Equal

18

-1.22

0.2397

8-iso

Satterthwaite Unequal

4.22

-0.74

0.4980

The statistical analysis (Satterthwaite Test for normally distributed data with
different variances) failed to show a difference between the two means of the data groups
as the p-value was greater than 0.05.
The power of the study was calculated and shown to be .518.
Table 10. Variables involved in power calculations
Μ1
N1=15
11.513

μ2
N2=5
17.34

σ
4.9659

σ

Α

17.355 0.05

Critical Value

Power

4.84434

.518

Because β = 1 – Power, beta (or the probability of making a type II error) was
calculated to be equal to 48.2%.
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Conclusions
To reiterate, the question of interest has been whether a difference exists in the
average 8-isoprostane levels between two groups: Pregnant Females and Non-Pregnant
Females aged 18-35 years.
When analyzing the demographic characteristics of the two groups it became
evident that two subjects in the non-pregnant group could be excluded. One subject
reported a history of childhood asthma; another reported a history of food allergies. Both
of these subjects were excluded from data calculations. Subject A10 self reported a
history of childhood asthma; her 8-isoprostane concentration was 16.692 pg/ml. The
subject A8 self reported a history of food allergy; her 8-isoprostane concentration was
10.035. All other data collected from subjects was used for calculations.
The means of the non-pregnant and pregnant groups was 11.513 and 17.34
respectively. There is an obvious difference between these two means, but is this
difference statistically significant? According to the t-test performed on the two means
there was not a statistical difference found. The null hypothesis stated that there was no
difference in the exhaled breath condensate oxidative marker PGF2α in pregnant females
in their third trimester of pregnancy versus non-pregnant females. The alternative
hypothesis stated that there was a difference between the exhaled breath condensate
oxidative marker PGF2α in pregnant females in their third trimester of pregnancy versus
non-pregnant females. Based on our t-test we must fail to reject the null hypothesis.
As to why a difference between the two groups was not found could primarily be
due to the sample size of the study. Power is largely affected by sample size, that is, if
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the sample study size is small the study will have insufficient power to detect real
associations. Since Power = 1-β the smaller the power the larger the beta (probablility of
not finding an association in a sample when one exists in the population).
The standard deviations of both the pregnant group and non-pregnant group were
large; 4.966 and 17.355 respectively. This could be in part due to the distribution of 8isoprostanes in females, both pregnant and non-pregnant is large in nature. However, we
cannot statistically confirm this as our sample size is not large enough for us to conclude
that we have statistically found a difference between the two means.
As previously discussed, Staff, et.al. reported an increased content of lipid
peroxides in preeclamptic decidual placental tissue in preeclamptic patients at delivery
compared with controls.8 Another study by Moretti and colleagues demonstrated
increased markers of oxidative stress in preeclamptic women versus uncomplicated
pregnancy and non-pregnant controls by measuring various volatile organic compounds
in the exhaled breath condensate of these women9 This study analyzed non-pregnant,
healthy pregnant and preeclamptic pregnant females. We sought out to determine if a
difference exists between baseline levels of 8-isoprostanes between a group of healthy
pregnant females and non-pregnant females. This difference between the means of the
two data sets was shown and is an observed difference, however is not a statistically
significant difference.
The implication that the crude means of the two groups indicated an observable
difference but not a statistically significant difference provides a basis for the need of
future studies. Future studies would need to address the necessity of larger sample sizes
29

in each group. This serves as a challenge as participant recruitment of pregnant females
in their 3rd trimester was low in this study.

30

References
1. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary
pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001;280(6):L1067-82.
2. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ.
Increased 8-Isoprostane, a Marker of Oxidative Stress, in Exhaled Condensate of Asthma
Patients. Am J Respir Crit Care Med 1999;160(1):216-20.
3. Van Hoydonck PGA, Wuyts WA, Vanaudenaerde BM, Schouten EG, Dupont LJ,
Temme EHM. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled
breath condensate. Eur Respir J 2004;23(2):189-92.
4. Baraldi E, Carraro S, Alinovi R, et al. Cysteinyl leukotrienes and 8-isoprostane in
exhaled breath condensate of children with asthma exacerbations. Thorax
2003;58(6):505-9.
5. Baraldi E, Ghiro L, Piovan V, et al. Increased Exhaled 8-Isoprostane in Childhood
Asthma. Chest 2003;124(1):25-31.
6. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway
inflammation and asthma. Eur Respir J 2003;21(1):177-86.
7. Goil S, Truog WE, Barnes C, Norberg M, Rezaiekhaligh M, Thibeault D. Eight-epiPGF2[alpha]: A possible marker of lipid peroxidation in term infants with severe
pulmonary disease. The Journal of Pediatrics 1998;132(2):349-51.
8. Staff AC, Halvorsen B, Ranheim T, Henriksen T. Elevated level of free 8-isoprostaglandin F2[alpha] in the decidua basalis of women with preeclampsia. American
Journal of Obstetrics and Gynecology 1999;181(5):1211-5.
9. Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased breath
markers of oxidative stress in normal pregnancy and in preeclampsia. American Journal
of Obstetrics and Gynecology 2004;190(5):1184-90.
10. Murphy VE, Gibson PG, Smith R, Clifton VL. Asthma during pregnancy:
mechanisms and treatment implications. Eur Respir J 2005;25(4):731-50.
11. Held H-D, Uhlig S. Mechanisms of Endotoxin-Induced Airway and Pulmonary
Vascular Hyperreactivity in Mice. Am J Respir Crit Care Med 2000;162(4):1547-52.
31

12. Holz O. Catching breath: monitoring airway inflammation using exhaled breath
condensate. Eur Respir J 2005;26(3):371-2.
13. Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and
Analysis of Exhaled Breath Condensate in Humans. Am J Respir Crit Care Med
2001;164(5):731-7.

32

Appendices

33

Appendix A: Questionnaire Form

Health Questionnaire
What is your date of birth?___________________________
Your current age?____________________________
What is your current
occupation?_________________________________
Have you ever been pregnant?

YES

NO

G___P___A___
Are you currently pregnant?

YES

NO

EDC_________
When was your last menstrual
period?___________________________________
Do you have any medical complications related to your pregnancy such as diabetes,
hypertension, morning sickness, etc? YES NO
If yes,
what conditions?__________________________________________________
Do you smoke?

YES

NO

Are you exposed to second hand smoke?
Have you ever smoked?

YES

YES

NO

NO

How many packs per day did you smoke?___________________
For how many years did you smoke?_______________________
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When did you quit smoking? _______________________________________________
Do you have any medical problems?

YES

NO

Please list them here.

•

_________________________________________________________________

•

__________________________________________________________________

•

__________________________________________________________________

Have you ever had any of the following conditions?
•

Chest pain, palpitations, irregular heart beat, or heart disease?

•

High blood pressure?

•

Asthma, bronchitis, emphysema, or other lung disorder?

YES

YES

NO

NO
YES

NO

Do you see your health care provider on a routine basis for any medical condition?
YES

NO

If so, what?______________________________________________________________
Do you take any prescription or over-the-counter medications?

YES

NO

If so,

what?
•

________________________________________________________________

•

________________________________________________________________

•

__________________________________________________________________

When is the last time you remember being ill?_______________
What illness did you have?___________________________________________
To what degree do you have the following symptoms at this time?
Cough:

NONE
VERY MUCH
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A LITTLE

MODERATE

Appendix A (Continued)
Phlegm production:

NONE
VERY MUCH

A LITTLE

MODERATE

Itchy or runny nose:

NONE
VERY MUCH

A LITTLE

MODERATE

Throat irritation:

NONE
VERY MUCH

A LITTLE

MODERATE

Chest tightness or pain:

NONE
VERY MUCH

A LITTLE

MODERATE

Have you been exposed to any gases, dusts, or fumes at home or on the job?

YES

NO
If so, please explain:
________________________________________________________________________
________________________________________________________________________
_______________________________________________________________________
Post Study Questionnaire
Did you have any concerns about the way the informed consent process was handled?
YES

NO

Did you have any problems with the Health Questionnaire?

YES

Did you have any discomfort or concerns after the physical exam?
Did you have any discomfort or concerns after the nitric oxide test?

NO
YES

NO

YES

NO

Did you have any discomfort or concerns after completing the spirometry?

YES

Please elaborate. Use the back of this page is necessary.
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Appendix B: Adult University of South Florida Informed Consent Document

Informed Consent for an Adult
University of South Florida
Information for People Being Asked to Take Part in Research Studies
IRB Study #103718c
Doctors and researchers at University of South Florida (USF) study diseases and other
health problems people have. We try to find better ways to help treat these health
problems. To do this, we need the help of people who agree to take part in a research
study.
Title of Research Study: 8-isoprostane levels in exhaled breath condensate of
pregnant women compared to non-pregnant women, is there a baseline difference?
Person in Charge of Study: Rosemary Szollas, M.D. and Stuart Brooks, M.D.;
Karen Olson, M.D.
Where the study will be done: University of South Florida, College of Public
Health, MHH Room 323
Who is paying for the study: Sunshine Education Resource Center

Should you take part in this study?
This form tells you about this research study. You can decide if you want to take part in
it. You do not have to take part. Reading this form should help you decide if you want
to take part in the study. If, at any time, you have any questions feel free to ask the
person explaining this study to you.
Before you decide:
•

Read this form.

•

Talk about this study with the study doctor or the person explaining the study. You
can have someone with you when you talk about the study.

•

Find out what the study is about.

This form explains:
•

The purpose of this research study.

•

What will happen during this study and what you will need to do.

•

The potential benefits of being in this study, if any.

•

The risks of having problems because you are in this study.

•

The answers to any questions you might have.

You can ask questions:
•

You may have questions this form does not answer. If you do, ask the study doctor as
you go along.
37

Appendix B (Continued)
•

You don’t have to guess at things you don’t understand. Ask the people doing the
study to explain things in a way you can understand.

After you read this form, you can:
•

Take your time to think about the information that has been provided to you.

•

Have a friend or family member read the form.

•

Talk it over with your regular doctor.

It’s up to you. If you choose to be in the study, then you can sign the form. If you do
not want to take part in this study, you do not sign the form.

Why is this research being done?
The purpose of this study is to find out if:
•

The purpose of this study is to find out if there is an increased level of 8-isoprostane
in the exhaled breath condensate of pregnant women. 8-isoprostane is a chemical
made in the body naturally. The amount of 8-isoprostane also increases in the lungs
in some diseases of the lung. This study will help find out if pregnancy causes an
increase in the production of 8-isoprostane in the lungs.

•

This study will help find out if 8-isoprostane levels increase during pregnancy and
help in understanding of how pregnancy affects asthma.

•

To measure 8-isoprostane in the breath we need to collect your exhaled breath.
Breathing normally into a mouth size tube will do this. The tube is cooled to a very
low temperature thereby changing the gas you exhale into a liquid form. The liquid is
a suitable way to collect your breath and store it for analyzing.

Why are you being asked to take part?
We are asking you to take part in this study because you are a woman of child bearing
age who is pregnant or who is not pregnant. We need to compare these two groups.
In order to participate in this study, you need to be between 18 – 35 years of age, a
non-smoker with no history of asthma, environmental allergies, chronic illness, or
recent respiratory infection (in the past month). If you are pregnant, you need to be at
28 weeks gestation or more (as determined by your personal health care provider)
when you come to the Breath Lab for the study.

How long will you be asked to stay in the study?
You will be asked to spend about three hours in this study.
The sample collected from your breath will be stored for a maximum of three months, the
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analyzing of your sample will take about two hours, you will not be required to be
present for this portion of the study.
One hour includes the time it takes to complete the informed consent process and fill out
a health questionnaire. You may choose to take more time to complete the informed
consent.
A brief physical examination, collection of exhaled breath condensate and spirometry
will take about an hour.

How often will you need to come for study visits?
A study visit is one you have with the study doctor. This visit is different than the visits
you make with your regular doctor. You will need to come for one study visits in all.

How many other people will take part?
About fifty people will take part in this study at USF.

Will the medical treatment you get from your regular doctor
change if you take part in this study?
The kind of treatment you now get from your regular doctor will not change because you
take part in this study. The only way that it could potentially change is if we discover a
medical condition which was not previously diagnosed and your doctor chooses to treat
you for it.
You will keep seeing your regular doctor. Your regular doctor will give you the same
kind of treatment you would get anyway, whether you take part in the study or not.
This study includes only healthy women whose only condition requiring treatment should
be pregnancy. If you require any other treatment, please do not hesitate to get it. We
need you to inform us of any treatment in the month before testing or in the week
following testing, other than routine prenatal care, because it may affect or ability to use
your results in this study.
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What other choices do you have if you decide not to take part
in this study?
If you decide you do not want to take part in this study, that is okay. We are
performing some simple diagnostic tests. These are probably not necessary for your
medical care if you are being included in this study.
If you wanted or needed them done, your personal health care provider could perform
a physical examination and order spirometry. If you wanted to know the level of 8isoprostane in your breath, you would only be able to have it measured in a study
such as this one. It is an experimental study which is not generally available.

How do you get started?
If you decide to take part in this study, you will need to sign this consent form.
Then, we will do some screening tests. Screening tests are tests done to see if you are
able to be in the study. Screening tests are different from the actual study procedures.
The definition of screening is the application of a test to detect a potential disease or
condition in a person who has no known signs of that disease or condition. The screening
tests are done, therefore, prior to the actual study procedures to make sure the researchers
identify the correct population of individuals to include into the study.
We will do these screening tests:
1. The health questionnaire will be used to confirm whether you meet the criteria for
being involved in this study. In order to be included you need to
•

be a non-smoker

•

be 18 – 35 years of age

•

have no environmental allergies such as hay fever

•

have no chronic illnesses which require routine monitoring or treatment,
especially asthma or other pulmonary diseases

•

be twenty-eight or more weeks pregnant when you are scheduled to be tested

OR
•

be non-pregnant, having had a normal menstrual period in the month prior to
testing

2. The brief physical examination will include listening to your heart and lungs. In order
to be
included you need to have
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•

clear lung sounds without wheezing, rales, or rhonchi (abnormal lung sounds)

•

a regular heart beat without any murmurs, rubs, or gallops

There is not a separate visit to complete the screening tests. The results will be available
once the collected samples are analyzed. Then you and the research team will decide
whether or not you continue in the study.

What will you need to do to get ready for this study?
For one hour prior to your scheduled appointment at the Breath Lab, you will need to
refrain from eating, drinking, or performing any strenuous exercise such as running,
weight lifting, or heavy physical labor.

What will happen during this study?
You will need to complete five things to complete this study:
1. This informed consent document
2. A health questionnaire
3. A brief physical exam where we listen to your heart and lungs
4. Spirometry
5. The collection of exhaled breath condensate
If you have not completed the informed consent before you come to the Breath Lab, we
will complete it at the beginning of your visit. If you agree to participate in the study and
sign the informed consent, we will proceed.
The health questionnaire is a short assessment of your health history and any current
symptoms you may be experiencing. It will be used to collect demographic ( a group of
characteristics defining human populations) information about you such as your age and
medical information about your health history and recent symptoms.
After you complete the health questionnaire, the principal investigator (PI) will listen to
your heart and lungs. She needs to see if you have wheezing or rhonchi (abnormal breath
sounds) or an irregular heart beat or murmur. Any of these findings will probably result
in your withdrawal from the study.
Next, we will measure how fast you can blow the air out of your lungs and how much air
you can blow out in a test called spirometry. This test is used routinely to monitor people
of all ages who have lung disease. We are using it in our study to be certain that you do
not have any type of undiagnosed lung disease which would affect our results.
Spirometry takes about as much effort as blowing up a big balloon and is the most
difficult test to perform in this study. Once again, we need to have three acceptable
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measurements to complete this test. We will not repeat this test more than eight times
even if we do not get three acceptable tracings. Most people are able to complete this test
in five attempts or less.
You can take your time; you can take a break; or you can stop at any time.
Finally, your exhaled breath will be collected and cooled in order to condense (turn from
a gas to a liquid form) your breath into a liquid for collection and storage. In order to
collect your breath condensate we will ask you to breathe as you normally would through
a disposable tube. We will ask you to do this for a maximum of fifteen minutes, in order
to collect an adequate sample amount. If you need to break to cough, sneeze, or blow
your nose, or for any other reason you will be asked to remove your mouth from the tube
and resume breathing through the tube when comfortable once again. We can collect at
your pace if necessary. The time limit is not concrete as it is a recommended time period
for collection by the manufacturer of the collection device, however if adequate sample
size is obtained prior to fifteen minutes you may stop if you would like to do so.
After collection of exhaled breath condensate, we will ask you if you have any questions
about the tests, any discomfort at all, or any other concerns. All of these responses will
be recorded on your health questionnaire.

Will you be paid for taking part in this study?
Subjects will be offered twenty dollars upon completion of exhaled breath condensate
collection and for their time spent participating in the study.
If for any reason a subject is unable to complete the study, the following payment
schedule will be used:
1. Completion of exhaled breath condensate collection - $20
We are not able to reimburse you for additional costs you incur such as parking fees,
bus or taxi fare, childcare costs, or time away from work.

What will it cost you to take part in this study?
It
will not cost you anything to be part of the study.
You will have to pay for your regular care or any other costs. Your insurance
plan should cover your regular costs. Your insurance plan will not have to pay for
any study costs.

What are the potential benefits if you take part in this study?
We don’t anticipate that you will get any health benefits from taking part in this
study. We are performing diagnostic (used to identify disease or conditions) tests
only; not providing any treatment.
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You may potentially benefit by learning more about your health as a result of your
physical examination and testing during this study.
You may enjoy being part of a study and seeing how it is conducted.
No matter what, we will learn more about changes in the lungs during pregnancy.
What we learn may guide further research about asthma and pregnancy.

What are the risks if you take part in this study?
There is very little risk that you incur by being part of this study.
You may experience some discomfort during the collection of the exhaled breath
condensate or during the spirometry. Spirometry, in particular, requires you to blow
out as hard and fast as you can. This is something like blowing up a big, stiff balloon.
You could potentially get an infection in the Breath Lab. This is probably less likely
than getting an infection at the grocery store. Currently, all subjects being tested are
healthy subjects. Everyone gets a new, disposable mouthpiece to use. Anything that
gets contaminated is cleaned according to lab protocol.
Should you experience any adverse symptoms or event, you will be under the direct
supervision of a physician at all times during the study. We have emergency
equipment available and will call for emergency personnel (911) if needed.

Is there any risk to your unborn children if you take part in
this study?
This study does not involve any treatment which could affect you unborn child.
Two of the diagnostic studies which are being performed, physical examination and
spirometry, are routinely performed in pregnant women who have asthma without any
adverse outcome.
The experimental diagnostic study, collection and analyzing levels of exhaled breath
8-isoprostane, does not expose you to any physical, chemical, or biological hazard
which could potentially harm you or your unborn child. It is simply a measurement of
a common constituent in exhaled breath.

What if you get sick or hurt while you are in the study?
If you need emergency care:
•

Go to your nearest hospital or emergency room right away. Call 911 for
help. You should know that USF does not provide emergency care.

•

Call the study doctors as soon as you can. They will need to know that you are
hurt or ill. Call Rosemary Szollas, M.D., or Stuart Brooks, M.D. at (813) 97443
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7545.
•

If it is NOT an emergency, and you get hurt or sick while you are taking part
in this study:

•

Go to your regular doctor.

•

Please inform the study doctors. They will need to know if you are hurt or ill.
Call Rosemary Szollas, M.D. or Stuart Brooks, M.D. at (813) 974-7545.

•

The USF Medical Clinics may not be able to give the kind of help you need. You
may need to get help somewhere else.

If you are harmed while taking part in the study:
The state of Florida enjoys what is called "sovereign immunity." This means that you
usually cannot sue the state of Florida. However, the state has waived sovereign
immunity (agreed to be sued) in certain situations. One of those situations is if a state
employee, such as your study doctor or other USF employee, is negligent in doing his or
her job in a way that harms you during the study. The money that you might recover
from the state of Florida is limited in amount.
You can also call the USF Self Insurance Programs (SIP) at 1-813-974-8008 if you
think:
•

You were harmed because you took part in this study.

•

Someone from the study did something wrong that caused you harm, or didn’t do
something they should have done.

•

Ask the SIP to look into what happened.

Recruitment for this project has been conducted at a Tampa General clinical facility
therefore participation in this research project will make you subject to the
following:

ADULT TAMPA GENERAL INJURY STATEMENT
In the event you suffer an injury or illness as a result of participating in this research
study, please be aware that immediate, short-term medical treatment for the injuries or
illness will be available to you from Tampa General Hospital. The cost of the medical
treatment will be billed to you to the extent not covered by your insurance company or
government program or study sponsor. No other compensation will be offered. You are
not giving up any legal rights by signing this form. If you believe you have experienced
a reaction to the study medication or have been injured as a result of research procedures
performed at Tampa General Hospital, please contact the Department of Risk
Management at (813) 844-7666.
44

Appendix B (Continued)

What will we do to keep your study records private?
Federal law says we must keep your study records private. We have made prior
arrangements to do this.
To maintain subject confidentiality, each subject will be given a random three digit
subject number which will be recorded on the informed consent document and
compiled in a master list of all subjects. This number will be the only identifier listed
on the health questionnaire, the data collection form, the appointment list, spirometry
report, and sample storage tubes. Without the informed consent documents or the
master list, it will not be possible to link any confidential information to the subject.
The informed consent document and a master list of subjects will be kept in a locked
file cabinet in the Breath Lab or in the Occupational Medicine Residency Office.
Access to this material will only be available the investigators in the study.
Questionnaires and recorded data from the study will be kept in a locked file cabinet
in the Breath Lab or in the Occupational Medicine Residency office separate from the
informed consent documents and the master list whenever they are not in direct
possession of the investigators. These documents will not contain any information
which could, by itself, link them to you.
However, certain people may need to see your study records. By law, anyone who looks
at your records must keep them completely confidential. The only people who will be
allowed to see these records are:
The medical staff who are taking care of you.
Certain government and university people who need to know more about the study. For
example, individuals who provide oversight on this study may need to look at your
records. These include the University of South Florida Institutional Review Board (IRB)
and the staff that work for the IRB. Other individuals who work for USF that provide
other kinds of oversight may also need to look at your records. Other individuals who
may look at your records include: the Florida Department of Health, people from the
Food and Drug Administration (FDA) and the Department of Health and Human Services
(DHHS) (This is done to make sure that we are doing the study in the right way. They
also need to make sure that we are protecting your rights and your safety.)
We may publish what we find out from this study. If we do, we will not let anyone know
your name. We will not publish anything else that would let people know who you are.

What happens if you decide not to take part in this study?
You should only take part in this study if you want to take part.
If you decide not to take part:
•

You will not be in trouble or lose any rights you normally have.

•

You will still have the same health care benefits.
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•

You can still get your regular treatments from your regular doctor.

What if you join the study and decide you want to stop later
on?
You can decide after signing this informed consent document that you no longer want
to take part in this study. If you decide you want to stop taking part in the study, tell
the study staff as soon as you can.
•

You can stop at any time without any adverse outcome.

•

If you decide to stop, you can continue getting care from your regular doctor.

Are there reasons we might take you out of the study later
on?
Even if you want to stay in the study, there may be reasons we will need to take you
out of it. You may be taken out of this study if:
•

We find out it is not safe for you to stay in the study.

•

You experience a change in your health which is inconsistent with the study
criteria.

•

You miss your appointment at the Breath Lab twice without calling ahead of time
to reschedule.

You can get the answers to your questions.
If you have any questions about this study, call Rosemary Szollas, M.D. at (813) 9747545.
If you have questions about your rights as a person who is taking part in a study, call the
Division of Research Compliance of the University of South Florida at (813) 974-9343.
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Signatures for Consent to Take Part in this Research Study
It is up to you to decide whether you want to take part in this study. If you want to take
part, please read the statements below and sign the form if the statements are true.
I freely give my consent to take part in this study. I understand that this I am agreeing
to take part in research. I have received a copy of this consent form to take with me.
____________________________________________

___________

Signature of Person Taking Part in Study
Date
____________________________________________
Printed Name of Person Taking Part in Study
Optional - Witness
____________________________________________
Signature of Witness

___________
Date

____________________________________________
Printed Name of Witness
Statement of Person Obtaining Informed Consent
I have carefully explained to the person taking part in the study what he or she can
expect.
I hereby certify that when this person signs this form, to the best of my knowledge, he
or she understands:
What the study is about.
What needs to be done.
What the potential benefits might be.
What the known risks might be.
I also certify that he or she does not have any problems that could make it hard to
understand what it means to take part in this study. This person speaks the language
that was used to explain this study.
This person reads well enough to understand this form or, if not, this person is able to
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hear and understand when the form is read to him or her.
This person does not have a medical problem that makes it hard to understand what is
being explained and can, therefore, give informed consent.
This person is not taking drugs that make it hard to understand what is being
explained and can, therefore, give informed consent.
____________________________________________

___________

Signature of Person Obtaining Informed Consent

Date

__________________________________________________
Printed Name of Person Obtaining Informed Consent
Optional - Witness
____________________________________________
Signature of Witness

___________
Date

____________________________________________
Printed Name of Witness
Addendum to the Consent
Consent to take and store additional samples.
We are asking you to allow us to take and store additional samples of your exhaled breath
for use in the future. These samples may be used for a variety of purposes.
This means we will take some of your exhaled breath and cool it in order to collect the
liquid form of your breath. We will then freeze this small amount of liquid (about half of
a teaspoon) at below freezing temperatures in order to stabilize the compounds within
your breath. Once we are capable of analyzing your sample within the breath lab we will
de-thaw the sample and utilize it in a chemical assay kit that determines the concentration
of 8-isoprostane within your breath. Your entire sample collected will be used for this
technique and we will not discard any of the sample.
When you sign this below, you are agreeing to let us store and use your exhaled breath
condensate for future research studies.
We may use these samples to help us:


Determine if 8-isoprostane is elevated in the exhaled breath condensate of
pregnant women.



Help us with understanding how pregnancy affects asthma.

____ I give my consent to provide my exhaled breath condensate for that purpose.
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____ I do not give my consent to my exhaled breath condensate for that purpose.
____________________________________________

___________

Signature of Person Taking Part in Study Date
____________________________________________
Printed Name of Person Taking Part in Study
Optional - Witness
____________________________________________
Signature of Witness

___________
Date

____________________________________________
Printed Name of Witness

49

